n | Baseline | Day 90 | 95% CI (versus placebo) | P | |||
---|---|---|---|---|---|---|---|
Mean | SD | Mean | SD | ||||
Visual analogue scale score | |||||||
Placebo | 23 | 56.88 | 12.04 | 41.76 | 15.98 | <0.05 | |
100 mg 5-Loxin® | 24 | 57.05 | 8.71 | 21.37 | 7.13 | -27.67, -13.11 | <0.0001 |
250 mg 5-Loxin® | 23 | 55.62 | 9.26 | 14.22 | 6.8 | -34.94, -20.19 | <0.0001 |
Lequesne's Functional Index | |||||||
Placebo | 23 | 12.76 | 2.6 | 10.19 | 3.24 | 0.031 | |
100 mg 5-Loxin® | 24 | 12.1 | 2.76 | 7.78 | 4.61 | -4.74, -0.07 | <0.0001 |
250 mg 5-Loxin® | 23 | 12.04 | 3.03 | 7 | 3.5 | -5.19, -1.18 | <0.0001 |
WOMAC pain subscale | |||||||
Placebo | 23 | 38.04 | 2.03 | 31.74 | 2.58 | 0.1212 | |
100 mg 5-Loxin® | 24 | 42.08 | 2.93 | 19.17 | 3.55 | -21.33, to -3.83 | <0.0001 |
250 mg 5-Loxin® | 23 | 37.17 | 2.88 | 15.22 | 2.50 | -23.78 to -9.28 | <0.0001 |
WOMAC stiffness subscale | |||||||
Placebo | 23 | 33.15 | 2.73 | 24.45 | 2.37 | 0.2983 | |
100 mg 5-Loxin® | 24 | 31.77 | 3.61 | 14.06 | 3.71 | -38.87, -6.85 | <0.0001 |
250 mg 5-Loxin® | 23 | 27.72 | 3.44 | 9.24 | 2.07 | -43.35, -17.45 | <0.0001 |
WOMAC function subscale | |||||||
Placebo | 23 | 41.30 | 2.02 | 34.07 | 1.09 | 0.1048 | |
100 mg 5-Loxin® | 24 | 41.48 | 2.31 | 24.32 | 4.28 | -18.64, -0.82 | <0.0001 |
250 mg 5-Loxin® | 23 | 38.56 | 2.32 | 17.267 | 1.98 | -21.39, -12.23 | <0.0001 |
MMP-3 (ng/ml) | |||||||
Placebo | 15 | 902.1 | 275.6 | 928.5 | 216.02 | 0.4886 | |
100 mg 5-Loxin® | 16 | 893.6 | 270.1 | 637.2 | 224.5 | <0.0001 | |
250 mg 5-Loxin® | 14 | 926.9 | 270.5 | 497.5 | 167.5 | <0.0001 |